The decision to stop
Teva said it decided to stop the mid-stage study of emrusolmin because of a low probability of meeting its main goal if continued. The decision was based on the recommendation of an independent data monitoring committee after a pre-planned early analysis designed to assess whether the study was unlikely to succeed.
The company stressed that this was only an interim predictive assessment, not the study's final efficacy analysis.
No safety concerns
According to Teva, the interim analysis identified no safety concerns. Key points of the announcement include:
- The study was stopped because of a low likelihood of success, not for safety reasons.
- The decision followed an independent committee's recommendation.
- This was a predictive assessment, not the final efficacy result.
Stopping trials early when they are unlikely to succeed spares patients from continuing in a study with little promise and allows companies to redirect resources elsewhere.
















